Alharbi Adel S, Al-Hindi Mohammed Y, Alqwaiee Mansour, Al-Shamrani Abdullah, Alharbi Saleh, Yousef Abdullah, Alshammary Aisha, Miqdad Abeer, Said Yazan, Alnemri Abdulrahman, Alahmadi Turki, Almudeer Ali Husein
Department of Pediatrics, Prince Sultan Military City, Ministry of Defense, Riyadh, Saudi Arabia.
Department of Pediatric, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia.
Ann Thorac Med. 2024 Jul-Sep;19(3):190-200. doi: 10.4103/atm.atm_69_24. Epub 2024 Jul 4.
Respiratory syncytial virus (RSV) is the major cause of bronchiolitis among children under 5 years of age worldwide, accounting for a prevalence of 25%-88% in Saudi Arabia. Although no effective treatment for the virus exists, passive immunoprophylaxis reduced RSV hospitalizations in high-risk children. With recent advances in immunization, the Saudi Initiative of Bronchiolitis Diagnosis, Management, and Prevention panel screened recent relevant international guidelines, locally published data, and expert consensus to update guidelines for RSV prevention, taking into consideration the resources, timing, varying health profiles, and RSV burden in Saudi Arabia. The panel updated its recommendations to include immunization of infants, mothers, and older adults. Practical guidelines were prepared to facilitate the administration of the short-acting and newly developed long-acting RSV monoclonal antibodies (mAb) during the regular follow-ups of high-risk infants in specialized clinics. In addition, long-acting mAb was highlighted as all-infant protection in the routine immunization calendar.
呼吸道合胞病毒（RSV）是全球5岁以下儿童毛细支气管炎的主要病因，在沙特阿拉伯的患病率为25%-88%。尽管目前尚无针对该病毒的有效治疗方法，但被动免疫预防可减少高危儿童的RSV住院率。随着免疫接种的最新进展，沙特毛细支气管炎诊断、管理和预防倡议小组筛选了近期相关的国际指南、当地发表的数据以及专家共识，以更新RSV预防指南，同时考虑到沙特阿拉伯的资源、时机、不同的健康状况以及RSV负担。该小组更新了其建议，将婴儿、母亲和老年人的免疫接种纳入其中。制定了实用指南，以方便在专科诊所对高危婴儿进行定期随访时使用短效和新开发的长效RSV单克隆抗体（mAb）。此外，长效mAb在常规免疫接种计划中被强调为对所有婴儿的保护。
